Editorial: Short and long-term treatment options in patients with acute coronary syndrome.
作者信息
Landi Antonio, Varga Albert, Veulemans Verena, Milzi Andrea
机构信息
Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
Faculty of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland.
出版信息
Front Cardiovasc Med. 2025 Feb 4;12:1563882. doi: 10.3389/fcvm.2025.1563882. eCollection 2025.
Abstract
摘要
相似文献
1
Editorial: Short and long-term treatment options in patients with acute coronary syndrome.社论：急性冠状动脉综合征患者的短期和长期治疗选择
Front Cardiovasc Med. 2025 Feb 4;12:1563882. doi: 10.3389/fcvm.2025.1563882. eCollection 2025.
2
Ten-year outcomes of patients randomized to surgery, angioplasty, or medical treatment for stable multivessel coronary disease: effect of age in the Medicine, Angioplasty, or Surgery Study II trial.稳定多血管冠状动脉疾病患者随机接受手术、血管成形术或药物治疗的 10 年结果：Medicine, Angioplasty, or Surgery Study II 试验中年龄的影响。
J Thorac Cardiovasc Surg. 2013 Nov;146(5):1105-12. doi: 10.1016/j.jtcvs.2012.08.015. Epub 2012 Aug 31.
3
Comparison of Percutaneous Coronary Intervention, Coronary Artery Bypass Grafting and Medical Therapy in Non-ST Elevation Acute Coronary Syndrome Patients With 3-Vessel Disease.三血管病变非 ST 段抬高型急性冠脉综合征患者行经皮冠状动脉介入治疗、冠状动脉旁路移植术与药物治疗的比较。
Circ J. 2020 Sep 25;84(10):1718-1727. doi: 10.1253/circj.CJ-20-0300. Epub 2020 Aug 26.
4
Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.接受冠状动脉介入治疗后接受双联抗血小板治疗和三联治疗的患者的出血风险：ADAPTT 回顾性基于人群的队列研究。
Health Technol Assess. 2023 May;27(8):1-257. doi: 10.3310/MNJY9014.
5
Secondary prevention therapies following percutaneous coronary intervention or acute coronary syndrome in patients with diabetes mellitus.糖尿病患者经皮冠状动脉介入治疗或急性冠状动脉综合征后的二级预防疗法。
Front Cardiovasc Med. 2024 Nov 22;11:1436332. doi: 10.3389/fcvm.2024.1436332. eCollection 2024.
6
Percutaneous coronary intervention compared with coronary artery bypass graft in coronary artery disease patients with chronic kidney disease: a systematic review and meta-analysis.慢性肾脏病冠心病患者经皮冠状动脉介入治疗与冠状动脉旁路移植术的比较：一项系统评价和荟萃分析。
Ren Fail. 2014 Sep;36(8):1177-86. doi: 10.3109/0886022X.2014.934178. Epub 2014 Jul 2.
7
Sex disparity in secondary prevention pharmacotherapy and clinical outcomes following acute coronary syndrome.急性冠状动脉综合征后二级预防药物治疗及临床结局的性别差异。
Eur Heart J Qual Care Clin Outcomes. 2022 Jun 6;8(4):420-428. doi: 10.1093/ehjqcco/qcab007.
8
[Medication compliance for secondary prevention and long-term outcome among patients with acute coronary syndrome after percutaneous coronary intervention in different regions].不同地区经皮冠状动脉介入治疗后急性冠状动脉综合征患者二级预防用药依从性及长期预后
Zhonghua Xin Xue Guan Bing Za Zhi. 2021 Feb 24;49(2):143-149. doi: 10.3760/cma.j.cn112148-20200528-00442.
9
Long-Term Outcomes of Single-Vessel Percutaneous Coronary Intervention on Culprit Vessel vs. Multivessel Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Multivessel Coronary Artery Disease.多支血管病变非 ST 段抬高型急性冠脉综合征患者经皮冠状动脉介入治疗罪犯血管与多支血管病变的长期预后比较。
Circ J. 2021 Jan 25;85(2):185-193. doi: 10.1253/circj.CJ-20-0369. Epub 2021 Jan 9.
10
Impacts of intensive follow-up on the long-term prognosis of percutaneous coronary intervention in acute coronary syndrome patients - a single center prospective randomized controlled study in a Chinese population.强化随访对急性冠脉综合征患者经皮冠状动脉介入治疗长期预后的影响——一项中国人群单中心前瞻性随机对照研究
Eur J Prev Cardiol. 2016 Jul;23(10):1077-85. doi: 10.1177/2047487315607041. Epub 2015 Sep 28.
本文引用的文献
1
Abbreviated or Standard Antiplatelet Therapy After PCI in Diabetic Patients at High Bleeding Risk.糖尿病患者高出血风险经皮冠状动脉介入治疗（PCI）后采用简化或标准抗血小板治疗。
JACC Cardiovasc Interv. 2024 Nov 25;17(22):2664-2677. doi: 10.1016/j.jcin.2024.08.030.
2
Multimodal Intravascular Imaging of the Vulnerable Coronary Plaque.易损性冠状动脉斑块的多模态血管内影像学检查
Echocardiography. 2024 Nov;41(12):e70035. doi: 10.1111/echo.70035.
3
Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome.急性冠状动脉综合征后 12 个月双联抗血小板治疗的当代作用解析。
Circulation. 2024 Jul 23;150(4):317-335. doi: 10.1161/CIRCULATIONAHA.124.069012. Epub 2024 Jul 22.
4
Coronary embolisation of native aortic valve debris during transcatheter aortic valve replacement: mechanical embolectomy and histopathological analysis.
Lancet. 2024 Jan 13;403(10422):e5-e6. doi: 10.1016/S0140-6736(23)02623-5.
5
Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines.急性冠状动脉综合征患者的抗栓治疗：欧洲专家共识文件与2023年欧洲心脏病学会指南的异同
Eur Heart J Acute Cardiovasc Care. 2024 Feb 9;13(1):173-180. doi: 10.1093/ehjacc/zuad158.
6
2023 ESC Guidelines for the management of acute coronary syndromes.2023年欧洲心脏病学会急性冠状动脉综合征管理指南。
Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191.
7
Global epidemiology of acute coronary syndromes.急性冠状动脉综合征的全球流行病学
Nat Rev Cardiol. 2023 Nov;20(11):778-788. doi: 10.1038/s41569-023-00884-0. Epub 2023 May 25.
8
Antithrombotic therapy in patients with established atherosclerotic coronary disease.
Heart. 2023 Jun 14;109(13):1034-1043. doi: 10.1136/heartjnl-2022-321603.
9
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease.稳定性冠心病患者的抗血栓治疗策略。
Eur Heart J Cardiovasc Pharmacother. 2023 Jul 29;9(5):462-496. doi: 10.1093/ehjcvp/pvad032.
10
Abbreviated or Standard Antiplatelet Therapy in HBR Patients: Final 15-Month Results of the MASTER-DAPT Trial.HBR 患者的抗血小板治疗：MASTER-DAPT 试验的最终 15 个月结果。
JACC Cardiovasc Interv. 2023 Apr 10;16(7):798-812. doi: 10.1016/j.jcin.2023.01.366.
Zotero 插件